Our mission is to develop transformational genetic medicines utilizing novel gene editing delivery technologies, with an emphasis on diseases with significant unmet medical need. Our team is advancing multiple innovative approaches to deliver a variety of therapeutic payloads, focusing initially on gene editing in therapeutically relevant cells and tissues. Our world class scientific founders include Professor David Liu (HHMI, Broad and Harvard) and Professor Keith Joung (MGH and Harvard), and we are funded with a significant capital investment by leading life science venture capital firms including Newpath Partners, Atlas Venture, F-Prime Capital, and 5AM Ventures. We believe that our technology has the potential to positively impact patients suffering from severe genetic diseases, and we are committed to building an excellent, science-driven and diverse team that is passionate about making a difference. Nvelop Therapeutics is a stealth-mode biotechnology company based in Cambridge, MA.

We are always looking for great talent, so please contact us at careers@NvelopTx.com for all enquiries !

View the Nvelop Therapeutics website